drozitumab
Drozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells. Drozitumab was developed by Genentech. — Wikipedia
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Jun 1, 2007 (NCT00543712)
Timeline
Indications
Mechanism of action
TNFRSF10B agonist
Induces TNFRSF10B clustering at the cell surface and stimulates a death-inducing signaling complex containing the adaptor molecule Fas-associated death domain and the apoptosis-initiating protease caspase-8. Fc crosslinking further augmented Drozitumab's proapoptotic activity.
Binds to TNFRSF10B, but shows no detectable binding to any of the other Apo2L/TRAIL receptors.
Binds at the junction between CRD2 and CRD3, interacting with residues in both CRD2 and CRD3.
TNFSF10 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDrozitumab ↗
- ChEMBLCHEMBL1743008 ↗
Also known as
- anti-dr5 rhumab-dr5
- drozitumab
- drozitumab
- pro95780
- pro95780
- pro 95780
- pro-95780
- pro-95780
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00851136 | Phase 1 | May 1, 2009 | Genentech |
| NCT00517049 | Phase 2 | Mar 1, 2008 | Genentech |
| NCT00497497 | Phase 1 | Oct 1, 2007 | Genentech |
| NCT00480831 | Phase 2 | Jun 1, 2007 | Genentech |
| NCT00543712 | Phase 2 | Jun 1, 2007 | Genentech |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genentech | For profit | 5 | 5 | 2 | 2007 |